Jazz Pharmaceuticals Plc Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated May 5, 2021, details the completion of a major acquisition and the execution of a new credit facility by Jazz Pharmaceuticals Plc (the "Company"). The primary event is the closing of the acquisition of GW Pharmaceuticals plc ("GW") via a scheme of arrangement, making GW an indirect wholly-owned subsidiary of the Company.
Key Financial Metrics and Transaction Details
- Acquisition Consideration: GW shareholders received $16.662/3 in cash plus 0.010030 Jazz Ordinary Shares per GW share. GW ADS holders received $200 in cash (less fees) and 12 times the share deliverable per ADS.
- Equity Issuance: Approximately 3,798,105 Jazz Ordinary Shares were issued to GW shareholders in connection with the transaction.
- Debt Financing: The Company entered into a new Credit Agreement on May 5, 2021, comprising:
- $3.1 billion seven-year Term Loan B (USD).
- €625 million seven-year Term Loan B (EUR).
- $500 million five-year Revolving Credit Facility (undrawn at closing).
- Use of Proceeds: Funds from the Term Loan Facility were used to repay the existing credit agreement, fund the cash portion of the GW acquisition, and pay related fees.
- Interest Rates: Term Loan margins are 3.50% (LIBOR/EURIBOR) or 2.50% (Prime). Revolving Credit margins range from 2.75% to 3.25% (LIBOR) or 1.75% to 2.25% (Prime), based on leverage ratios.
Material Changes and Executive Appointments
The filing reports the termination of the Company's existing credit agreement and the release of associated guarantees and liens. Additionally, Chris Tovey, formerly GW's Chief Operating Officer, was appointed as Jazz's Executive Vice President, Chief Operating Officer, and Managing Director Europe & International. His compensation package includes a £400,000 base salary, a 55% target cash bonus, a £750,000 retention bonus, and equity awards (RSUs and PSUs) with an approximate combined grant date value of $3 million.
Guidance, Risks, and Contingencies
The filing does not provide specific financial guidance or outlook for future periods. However, it outlines significant financial covenants tied to the new Revolving Credit Facility, including a maximum first lien secured net leverage ratio and a minimum interest coverage ratio, which apply only if amounts are drawn under the revolver. The Credit Agreement also contains customary restrictions on indebtedness, liens, investments, and dividends. Pro forma financial information regarding the acquisition is not included in this filing and is expected to be filed within 71 days.
Investor Verification Checklist
- Verify the final number of Jazz Ordinary Shares issued to GW shareholders and the total cash consideration paid.
- Review the full text of the Credit Agreement (Exhibit 10.1) for specific definitions of leverage ratios and interest rate floors.
- Monitor the upcoming filing of pro forma financial information to assess the combined entity's financial position.
- Confirm the vesting schedule and performance metrics for the new executive equity awards granted to Chris Tovey.
- Check for any subsequent amendments regarding the financial statements of the acquired business (GW).